Morbidity in patients on L-thyroxine
Patients on L-thyroxine with a 'suppressed' TSH (< 0.05 mU/l) were compared to those in whom TSH was detectable but not elevated (0.05-4.0 mU/l), with regard to morbidity data.
Biochemical data from Tayside Thyroid Register was matched to hospital admissions data obtained from Health Board Statistics.
The patients were identified from those registered on the computerized Tayside Register.
Serum T4 and TSH assays, clinical assessment scores, and admission records with regard to ischaemic heart disease, overall fractures, fractured neck of femur and breast carcinoma.
Over one year, 1180 patients on thyroxine replacement had clinical and biochemical assessment; 59% had a suppressed TSH and 38% 'normal' TSH. Patients with a suppressed TSH exhibited higher median serum thyroxine levels (146 nmol/l, range 77-252 vs 119 nmol/l, 58-224; P < 0.001). Patients under the age of 65 years on L-thyroxine had an increased risk of ischaemic heart disease compared to the general population (female 2.7 vs 0.7%, P < 0.001; male 6.4 vs 1.7%, P < 0.01), but the risk was no different between those with suppressed and normal TSH. There was no increase in risk for overall fracture, fractured neck of femur or breast carcinoma in those on thyroxine with suppressed or normal TSH.
Patients under the age of 65 years on L-thyroxine had an increased risk of ischaemic heart disease. There was no excess of fractures in patients on L-thyroxine even if the TSH is suppressed.
Leese GP, Jung RT, Guthrie C, Waugh N, Browning MC.
Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH.
Clin Endocrinol (Oxf).
University Department of Medicine, Ninewells Hospital and Medical School, Dundee, Scotland.